Compare ACADIA Pharmaceuticals Inc. (ACAD) vs GameStop Corp. (GME) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs GameStop Corp. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while GameStop Corp. trades at $21.69 (market cap $9.96B). The key difference: GameStop Corp. is far larger — about 2.2× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, GameStop Corp. nearer its low. Which is the better fit depends on your goals.
| ACAD | GME | |
|---|---|---|
Market Cap | $4.49B | $9.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $27.69 |
52-Week Low | $20.06 | $19.94 |
Enterprise Value | $3.69B | $5.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
GME trades at $22.2, down 2.72% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported a net income margin of 20.45% for 2025, with recent quarterly earnings beating expectations. Key developments include shareholder approval for increased share issuance and CEO Ryan Cohen's focus on a potential eBay acquisition, alongside a withdrawn $35 billion pay package to prioritize the takeover bid.
The outlook is mixed, with strong profitability and bullish technicals offset by a cautious analyst consensus and strategic risks from the eBay pursuit. Investment opportunities lie in continued earnings growth and strategic initiatives, while risks include integration challenges, competitive pressures in physical media, and reliance on CEO-driven strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →
